Pancreatic Cancer Research

ResearcherNational Health ServiceActive in the last 2 years

Rupaly Pandé

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-2346-373X; OpenAlex author ID A5042274599. Sources: OpenAlex.

Their work

Papers
25 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
93
Papers, trials and grants by year

2019: 1 paper · 2020: 3 papers · 2021: 3 papers · 2022: 1 paper · 2023: 4 papers · 2024: 7 papers · 2025: 4 papers · 2026: 2 papers

Papers 25

  1. Progression of sarcopenia among patients with pancreatic ductal adenocarcinoma receiving neoadjuvant therapy and the impact of pancreatic enzyme replacement th… Co-author DOI 10.1016/j.hbpd.2026.07.004↗
  2. Response to 'Towards an individualized strategy in perioperative chemotherapy for pancreatic cancer'. Co-author DOI 10.1038/s41416-025-03294-w↗
  3. Patterns, timing and predictors of recurrence following pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: an international multicentre retrospectiv… Co-author DOI 10.1016/j.hpb.2024.11.015↗
  4. Survival after neoadjuvant and induction FOLFIRINOX versus gemcitabine-nab-paclitaxel in patients with resected localised pancreatic adenocarcinoma: an interna… Co-author DOI 10.1038/s41416-025-03025-1↗
  5. Long-term Outcomes Following Resection of Adenocarcinoma Arising from Intraductal Papillary Mucinous Neoplasm (A-IPMN) Versus Pancreatic Ductal Adenocarcinoma … Co-author DOI 10.1097/sla.0000000000006272↗
  6. Validation of the PANAMA Score for Survival and Benefit of Adjuvant Therapy in Patients With Resected Pancreatic Cancer after Neoadjuvant FOLFIRINOX. Co-author DOI 10.1097/sla.0000000000006650↗
  7. Pathological Complete Response in Patients With Resected Pancreatic Adenocarcinoma After Preoperative Chemotherapy. Co-author DOI 10.1001/jamanetworkopen.2024.17625↗
  8. Five-year recurrence/survival after pancreatoduodenectomy for pancreatic adenocarcinoma: does pre-existing diabetes matter? Results from the Recurrence After W… Co-author DOI 10.1016/j.hpb.2024.04.010↗
  9. Using Data to Improve Healthcare: A Case Study of Pancreatic Enzyme Replacement in Pancreatic Cancer. Co-author DOI 10.1016/j.soncn.2024.151688↗
  10. Margin clearance greater than 1 mm in nodal-positive pancreatic adenocarcinoma patients: multicentre retrospective analysis. Co-author DOI 10.1093/bjsopen/zrae076↗
  11. Recurrent disease detection after resection of pancreatic ductal adenocarcinoma using a recurrence-focused surveillance strategy (RADAR-PANC): protocol of an i… Co-author DOI 10.1186/s13063-024-08223-5↗
  12. Correction: Recurrent disease detection after resection of pancreatic ductal adenocarcinoma using a recurrence-focused surveillance strategy (RADAR-PANC): prot… Co-author DOI 10.1186/s13063-024-08295-3↗
  13. Staging Computed Tomography Parameters Predict the Need for Vein Resection during Pancreaticoduodenectomy in Resectable Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/diagnostics14020135↗
  14. Are physical performance and frailty assessments useful in targeting and improving access to adjuvant therapy in patients undergoing resection for pancreatic c… Co-author DOI 10.1007/s00423-023-02828-1↗
  15. Oncological outcomes after pancreatoduodenectomy for pancreatic ductal adenocarcinoma in octogenarians: case-control study. Co-author DOI 10.1093/bjsopen/zrad053↗
  16. Surgical and Oncological Outcomes After Preoperative FOLFIRINOX Chemotherapy in Resected Pancreatic Cancer: An International Multicenter Cohort Study. Co-author DOI 10.1245/s10434-022-12387-2↗
  17. Vein Wall Invasion Is a More Reliable Predictor of Oncological Outcomes than Vein-Related Margins after Pancreaticoduodenectomy for Early Stages of Pancreatic … First author DOI 10.3390/diagnostics13223465↗
  18. Para-aortic lymph node involvement should not be a contraindication to resection of pancreatic ductal adenocarcinoma. Co-author DOI 10.4240/wjgs.v14.i5.429↗
  19. Clinical benefit of surveillance after resection of pancreatic ductal adenocarcinoma: A systematic review and meta-analysis. Co-author DOI 10.1016/j.ejso.2021.04.031↗
  20. Pancreatic enzyme replacement therapy in patients with pancreatic cancer: A national prospective study. Co-author DOI 10.1016/j.pan.2021.05.299↗
  21. Achieving 'Marginal Gains' to Optimise Outcomes in Resectable Pancreatic Cancer. First author DOI 10.3390/cancers13071669↗
  22. Evaluation of Adjuvant Chemotherapy in Patients With Resected Pancreatic Cancer After Neoadjuvant FOLFIRINOX Treatment. Co-author DOI 10.1001/jamaoncol.2020.3537↗
  23. Effect of time to surgery in resectable pancreatic cancer: a systematic review and meta-analysis. Co-author DOI 10.1007/s00423-020-01893-0↗
  24. Recurrence patterns of pancreatic cancer after pancreatoduodenectomy: systematic review and a single-centre retrospective study. Co-author DOI 10.1016/j.hpb.2020.01.005↗
  25. Determining Optimal Routes to Surgery for Borderline Resectable Venous Pancreatic Cancer-Where Is the Least Harm and Most Benefit? Co-author DOI 10.3389/fonc.2019.01060↗

Closest collaborators

The 25 strongest of 93 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Keith John Roberts · 17 shared papers, 2019–2026 · strength 2.94
  2. Robert Peter Sutcliffe · 5 shared papers, 2020–2024 · strength 0.77
  3. Nikolaos A. Chatzizacharias · 5 shared papers, 2020–2024 · strength 0.74
  4. Hanneke W.M. van Laarhoven · 4 shared papers, 2020–2025 · strength 0.52
  5. Marc G. Besselink · 4 shared papers, 2020–2025 · strength 0.52
  6. David Christopher Bartlett · 3 shared papers, 2022–2024 · strength 0.50
  7. Jyotsna Anand · 1 shared paper, 2026 · strength 0.43
  8. Asif Halimi · 3 shared papers, 2020–2025 · strength 0.42
  9. Lois A. Daamen · 3 shared papers, 2021–2024 · strength 0.42
  10. Izaak Quintus Molenaar · 3 shared papers, 2021–2024 · strength 0.42
  11. Hjalmar C. van Santvoort · 3 shared papers, 2021–2024 · strength 0.42
  12. Sarah F. Powell-Brett · 2 shared papers, 2021–2023 · strength 0.40
  13. Giuseppe Fusai · 3 shared papers, 2020–2025 · strength 0.37
  14. Johanna W. Wilmink · 3 shared papers, 2020–2024 · strength 0.37
  15. Manish Singh Ahuja · 2 shared papers, 2022–2023 · strength 0.31
  16. Robert C. Verdonk · 2 shared papers, 2024 · strength 0.30
  17. Hanne D. Heerkens · 2 shared papers, 2024 · strength 0.30
  18. Geertjan van Tienhoven · 2 shared papers, 2024 · strength 0.30
  19. Nadia Haj Mohammad · 2 shared papers, 2024 · strength 0.30
  20. Martijn Intven · 2 shared papers, 2024 · strength 0.30
  21. Gert J. Meijer · 2 shared papers, 2024 · strength 0.30
  22. Vincent Erwin de Meijer · 2 shared papers, 2024 · strength 0.30
  23. Ignace H. J. T. de Hingh · 2 shared papers, 2024 · strength 0.30
  24. Iris W.J.M. van Goor · 2 shared papers, 2024 · strength 0.30
  25. Paul C. M. Andel · 2 shared papers, 2024 · strength 0.30

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.